neurosymbolic-ai
(4)
The AI That Found More Patients, But Not More Minutes
Mendel.ai made oncology trial screening more accurate in a randomized study. The surprise: the human-plus-AI team took about as long as the humans alone.
Evidium
Evidium is a San Francisco healthcare-AI company building what it calls 'Referenced AI' - a neurosymbolic platform that turns medical evidence into computable knowledge. Rather than a black box, it projects patients across a computable map of clinical states and the transitions between them, so every insight traces back to guidelines, charts, and research. Founded and led by Carl Bate, the company sells transparent clinician-quality insights and probabilistic risk forecasts to health systems, insurers, and payviders, and closed a $22M Series A co-led by Health2047 (the AMA's venture studio) and WGG Partners in November 2025.
Kognitos
Kognitos is a Mountain View-based enterprise AI company that lets business users automate back-office operations by writing instructions in plain English. Its patented neurosymbolic platform, Koncierge, pairs the language understanding of large language models with a deterministic symbolic execution engine, aiming to run automations that are auditable and free of hallucinations. Founded in 2020 by former Nutanix CTO Binny Gill, the company pitches itself as a modern alternative to legacy RPA tools like UiPath and has raised roughly $85M across seed, Series A, and a $25M Series B.
Syntensor
Syntensor builds frontier AI foundation models for cellular biology and human genetics that simulate how drugs act inside the body before a single patient is dosed. Using dynamical systems simulation and neural differential equations over multi-omics data, its platform predicts drug efficacy, systemic toxicity, and the causes of clinical trial failure, then explains the mechanism behind each prediction. Founded out of the University of Cambridge and now headquartered in San Francisco, the company aims to build an accurate, interpretable mechanistic model of human physiology that de-risks pharmaceutical R&D.